ABL Bio Inc. (KOSDAQ:298380)
South Korea · Delayed Price · Currency is KRW 71,000
-1,700 (-2.34%)
Sep 1, 2026, 3:30 PM KST
ABL Bio Ratios and Metrics
Market cap in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 3,975,110 | 11,025,033 | 1,443,630 | 1,178,156 | 1,099,129 | 1,041,424 | |
Market Cap Growth | -20.48% | 663.70% | 22.53% | 7.19% | 5.54% | - |
Enterprise Value | 3,865,949 | 10,941,258 | 1,335,337 | 1,126,398 | 1,038,936 | - |
Last Close Price | 71000.00 | 200000.00 | 29900.00 | 24600.00 | 23000.00 | 22100.00 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | - | - | - | - | 342.55 | - |
Forward PE | 15900.44 | 277.59 | - | - | - | - |
PS Ratio | 115.95 | 138.94 | 43.22 | 17.97 | 16.33 | 195.31 |
PB Ratio | 22.85 | 70.36 | 8.63 | 15.90 | 15.81 | 18.61 |
P/TBV Ratio | 23.61 | 72.60 | 8.91 | 16.47 | 16.43 | 19.50 |
P/FCF Ratio | - | - | - | - | 15.69 | - |
P/OCF Ratio | - | - | - | - | 15.24 | - |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 112.77 | 137.89 | 39.98 | 17.18 | 15.44 | - |
EV/EBITDA Ratio | - | - | - | - | 321.37 | - |
EV/EBIT Ratio | - | - | - | - | 1144.20 | - |
EV/FCF Ratio | - | - | - | - | 14.83 | - |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.32 | 0.35 | 0.26 | 0.59 | 0.60 | 0.01 |
Debt / EBITDA Ratio | - | - | - | - | 12.94 | - |
Debt / FCF Ratio | - | - | - | - | 0.60 | - |
Net Debt / Equity Ratio | -0.64 | -0.38 | -0.58 | -0.37 | -0.52 | -0.77 |
Net Debt / EBITDA Ratio | 1.36 | 1.61 | 1.72 | 996.51 | -11.28 | 0.88 |
Net Debt / FCF Ratio | 2.37 | 0.97 | 1.25 | 0.80 | -0.52 | 1.03 |
Asset Turnover | 0.13 | 0.31 | 0.17 | 0.38 | 0.54 | - |
Quick Ratio | 1.69 | 1.41 | 2.24 | 1.71 | 1.09 | 5.01 |
Current Ratio | 1.72 | 1.43 | 2.28 | 1.81 | 1.12 | 5.20 |
Return on Equity (ROE) | -44.26% | -23.38% | -46.01% | -3.69% | 5.12% | - |
Return on Assets (ROA) | -20.79% | -9.84% | -18.93% | -0.95% | 0.45% | - |
Return on Capital Employed (ROCE) | -49.30% | -25.70% | -35.20% | -2.20% | 0.80% | -90.30% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | -1.98% | -0.34% | -3.85% | -0.22% | 0.29% | -4.18% |
FCF Yield | -1.18% | -0.56% | -5.43% | -2.90% | 6.38% | -4.02% |
Buyback Yield / Dilution | -14.30% | -7.25% | -0.37% | -0.58% | -1.27% | - |